Latest Announcements
Ladenburg Thalmann Acts as Sole Book-Running Manager for Salarius Pharmaceuticals, Inc. (SLRX) in its $23 Million Follow-On Offering
Transaction Information Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) announced the closing of its previously announced underwritten public offering of 16,806,722 shares of its common stock, including 2,192,181...
Ladenburg Thalmann Acts as Co-Manager for Cyclacel Pharmaceuticals, Inc. (CYCC) in its $14.5 Million Follow-On Offering
Transaction Information Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced the closing of its previously announced underwritten public offering of 2,078,214 shares of its common stock, offered at a price of...
Ladenburg Thalmann Acts as Sole Book-Running Manager for CHF Solutions, Inc. (CHFS) in its $20.9 Million Follow-On Offering
Transaction Information CHF Solutions, Inc. (NASDAQ: CHFS) announced the closing of its previously announced underwritten public offering of 3,795,816 shares of its common stock at a price to the public of $5.50...
Ladenburg Thalmann Acts as Co-Placement Agent for 4D pharma plc (LBPS) in its $25 Million Private Placement
4D pharma plc (NASDAQ: LBPS), announced the completion of its private placement in connection with its merger with Longevity Acquisition Corporation. A select group of U.S. and United Kingdom institutional investors...
Ladenburg Thalmann Acts as Joint Book-Running Manager for Windtree Therapeutics, Inc. (WINT) in its $30.0 Million Follow-On Offering
Transaction Information Windtree Therapeutics, Inc. (NASDAQ: WINT) announced the closing of its previously announced public offering of 9,230,500 shares of its common stock, par value $0.001 per share, together with...
Ladenburg Thalmann Acts as Lead Manager for Evaxion Biotech A/S (EVAX) in its $30 Million Initial Public Offering
Transaction Information Evaxion Biotech A/S (NASDAQ: EVAX) announced the closing of its initial public offering of 3,000,000 American Depositary Shares ("ADSs") at a public offering price of $10.00 per ADS. The...
Ladenburg Thalmann Acts as Sole Book-Runner for Helius Medical Technologies, Inc. (HSDT) in its $11 Million Follow-On Offering Priced At Market
Transaction Information Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX: HSM) announced the closing of an underwritten public offering of units for gross proceeds of approximately $11.0 million, which...
Ladenburg Thalmann Acts as Co-Manager for Krystal Biotech, Inc. (KRYS) in its $143 Million Follow-On Offering
Transaction Information Krystal Biotech, Inc. (NASDAQ: KRYS) announced that it has priced the previously announced underwritten public offering of 2,211,538 shares of its common stock at a public offering price...
Ladenburg Thalmann Acts as Sole Book-Runner for Hancock Jaffe Laboratories, Inc. (HJLI) in its Upsized $41 Million Follow-On Offering
Transaction Information Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI) announced that it has successfully completed a public offering of its securities generating approximately $41.4 million of gross proceeds,...
Ladenburg Thalmann Acts as Co-Manager for Nano-X Imaging Ltd. (NNOX) in its $193.2 Million Secondary Offering
Transaction Information Nano-X Imaging LTD (NASDAQ: NNOX) announced that it has priced the previously announced underwritten public offering of 3,091,635 ordinary shares by certain non-officer, non-director...
Ladenburg Thalmann Acts as Co-Manager for Bionano Genomics, Inc. (BNGO) in its $101.7 Million Follow-On Offering
Transaction Information Bionano Genomics, Inc. (NASDAQ: BNGO) announced the closing of its previously announced underwritten public offering of 33,368,851 shares of its common stock, including 4,352,458 shares...
Ladenburg Thalmann Acts as Exclusive Placement Agent for Jaguar Health, Inc. (JAGX) in its $15 Million Registered Direct Offering Priced Above-the-Market
Transaction Information Jaguar Health, Inc. (NASDAQ: JAGX) announced it has entered into a securities purchase agreement with two institutional investors including a high-net-worth family office for the purchase...